Incyte elects Susanne Schaffert, former Novartis Oncology President, to board

INCYTE CORP

Effective Oct 1, 2022, board increased to nine members, elected Susanne Schaffert.
Dr. Schaffert spent 26 years at Novartis, most recently President of Novartis Oncology (Jan 2019–Apr 2022).
She will serve as a non-employee director and receive standard cash/equity compensation.
No arrangement, family relationship, or reportable transaction exists with Dr. Schaffert.
She also serves on the board of Rubius Therapeutics, Inc.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Susanne Schaffert

Director

INCY · INCYTE CORP

Effective: 2022-10-01
Filed: October 4, 2022, 7:59 PM ET

Election of Directors Effective October 1, 2022, the Board of Directors of Incyte Corporation (the “Company”) increased the number of authorized members of the Board of Directors of the Company to nine and elected Susanne Schaffert, Ph.D., a member of the Board of Directors of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Susanne Schaffert was elected as Director at INCYTE CORP.

Action: elected
Role: Director

Exact text from the filing

Election of Directors Effective October 1, 2022, the Board of Directors of Incyte Corporation (the “Company”) increased the number of authorized members of the Board of Directors of the Company to nine and elected Susanne Schaffert, Ph.D., a member of the Board of Directors of the Company.

View on SEC.gov

INCYTE CORP filing history →

Source: SEC EDGAR

accession 0001104659-22-105577

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.